SK284343B6 - Použitie 40-O-(2-hydroxy)etyl-rapamycínu - Google Patents

Použitie 40-O-(2-hydroxy)etyl-rapamycínu Download PDF

Info

Publication number
SK284343B6
SK284343B6 SK1327-98A SK132798A SK284343B6 SK 284343 B6 SK284343 B6 SK 284343B6 SK 132798 A SK132798 A SK 132798A SK 284343 B6 SK284343 B6 SK 284343B6
Authority
SK
Slovakia
Prior art keywords
rapamycin
pharmaceutical composition
hydroxy
ethyl
rejection
Prior art date
Application number
SK1327-98A
Other languages
English (en)
Slovak (sk)
Other versions
SK132798A3 (en
Inventor
Walter Schuler
Hendrik Schuurman
Gisbert Weckbecker
Hans-G�Nter Zerwes
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10791127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK284343(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SK132798A3 publication Critical patent/SK132798A3/sk
Publication of SK284343B6 publication Critical patent/SK284343B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SK1327-98A 1996-03-27 1997-03-26 Použitie 40-O-(2-hydroxy)etyl-rapamycínu SK284343B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9606452.2A GB9606452D0 (en) 1996-03-27 1996-03-27 Organic compounds
PCT/EP1997/001548 WO1997035575A1 (en) 1996-03-27 1997-03-26 Use of rapamycin derivatives in vasculopathies and xenotransplantation

Publications (2)

Publication Number Publication Date
SK132798A3 SK132798A3 (en) 1999-03-12
SK284343B6 true SK284343B6 (sk) 2005-02-04

Family

ID=10791127

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1327-98A SK284343B6 (sk) 1996-03-27 1997-03-26 Použitie 40-O-(2-hydroxy)etyl-rapamycínu

Country Status (30)

Country Link
US (5) US6384046B1 (xx)
EP (3) EP2008657B1 (xx)
JP (2) JP2000507226A (xx)
KR (2) KR20070083654A (xx)
CN (1) CN1124135C (xx)
AT (1) ATE224194T1 (xx)
AU (1) AU716514B2 (xx)
BR (1) BR9708358A (xx)
CA (1) CA2247275C (xx)
CY (1) CY2404B1 (xx)
CZ (1) CZ292483B6 (xx)
DE (1) DE69715611T2 (xx)
DK (2) DK0893996T3 (xx)
ES (2) ES2184078T3 (xx)
GB (1) GB9606452D0 (xx)
HK (1) HK1018688A1 (xx)
HU (1) HU226422B1 (xx)
ID (1) ID17195A (xx)
IL (1) IL125812A (xx)
MY (1) MY117798A (xx)
NO (1) NO316667B1 (xx)
NZ (1) NZ331463A (xx)
PL (1) PL187732B1 (xx)
PT (2) PT2008657E (xx)
RU (1) RU2214247C2 (xx)
SI (1) SI2008657T1 (xx)
SK (1) SK284343B6 (xx)
TR (1) TR199801919T2 (xx)
WO (1) WO1997035575A1 (xx)
ZA (1) ZA972719B (xx)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
CA2261666C (en) 1996-07-30 2010-09-14 Novartis Ag Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
AU4565000A (en) * 1999-05-10 2000-11-21 Novartis Ag Organic compounds
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20070141107A1 (en) * 2000-03-15 2007-06-21 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
CA2400319C (en) 2000-03-15 2008-09-16 Orbus Medical Technologies Inc. Coating that promotes endothelial cell adherence
US8460367B2 (en) * 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20030229393A1 (en) * 2001-03-15 2003-12-11 Kutryk Michael J. B. Medical device with coating that promotes cell adherence and differentiation
US20070055367A1 (en) * 2000-03-15 2007-03-08 Orbus Medical Technologies, Inc. Medical device with coating that promotes endothelial cell adherence and differentiation
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US20020013335A1 (en) * 2000-06-16 2002-01-31 American Home Products Corporation Method of treating cardiovascular disease
EP1709974A3 (en) * 2000-06-16 2006-12-06 Wyeth Method of treating cardiovascular disease using rapamycin
US6670355B2 (en) * 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
MXPA03002871A (es) 2000-09-29 2004-12-06 Johnson & Johnson Dispositivos medicos recubiertos.
EP2269603B1 (en) * 2001-02-19 2015-05-20 Novartis AG Treatment of breast tumors with a rapamycin derivative in combination with exemestane
US8741378B1 (en) 2001-06-27 2014-06-03 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device
US6939376B2 (en) 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7682387B2 (en) * 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US20040024450A1 (en) * 2002-04-24 2004-02-05 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
JP2005525911A (ja) * 2002-05-20 2005-09-02 オーバス メディカル テクノロジーズ インク． 移植可能な薬物溶出医療用デバイス
US8109987B2 (en) 2003-04-14 2012-02-07 Tryton Medical, Inc. Method of treating a lumenal bifurcation
US7279174B2 (en) 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US7220755B2 (en) * 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
US9114198B2 (en) 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
EP2946666B1 (en) * 2004-04-30 2017-11-15 OrbusNeich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods of using same
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US8709469B2 (en) 2004-06-30 2014-04-29 Abbott Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7901451B2 (en) 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
EP1838288A4 (en) * 2004-12-20 2010-08-04 Ariad Pharma Inc THERAPEUTIC MATERIALS AND METHODS
EA015922B1 (ru) 2005-11-14 2011-12-30 Ариад Фармасьютикалз, Инк. ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ
US20080317814A1 (en) * 2005-11-17 2008-12-25 Access Plus Co., Ltd. Tube for Connecting Marteriovenous and Interposition for Medical Operation
US20070173923A1 (en) * 2006-01-20 2007-07-26 Savage Douglas R Drug reservoir stent
WO2008033956A2 (en) 2006-09-13 2008-03-20 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US20080097591A1 (en) * 2006-10-20 2008-04-24 Biosensors International Group Drug-delivery endovascular stent and method of use
US8067055B2 (en) * 2006-10-20 2011-11-29 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method of use
US20080103584A1 (en) 2006-10-25 2008-05-01 Biosensors International Group Temporal Intraluminal Stent, Methods of Making and Using
KR100930167B1 (ko) * 2007-09-19 2009-12-07 삼성전기주식회사 초광각 광학계
US8661630B2 (en) 2008-05-21 2014-03-04 Abbott Cardiovascular Systems Inc. Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
EP3459572A1 (en) 2007-11-14 2019-03-27 Biosensors International Group, Ltd. Automated coating method
US8921642B2 (en) * 2008-01-11 2014-12-30 Massachusetts Eye And Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
WO2010040064A1 (en) * 2008-10-03 2010-04-08 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US8366763B2 (en) 2009-07-02 2013-02-05 Tryton Medical, Inc. Ostium support for treating vascular bifurcations
US8685433B2 (en) 2010-03-31 2014-04-01 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
UA104738C2 (ru) 2011-05-18 2014-03-11 Олег Миколайович Лазаренко Композиция для повышения биосовместимости имплантатов и клеток для трансплантации с организмом реципиента и способ ее приготовления
CN102268015B (zh) * 2011-08-30 2013-08-28 成都摩尔生物医药有限公司 一种依维莫司的合成方法
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
KR101723265B1 (ko) 2013-08-16 2017-04-04 가톨릭대학교 산학협력단 mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
AU2014326794B2 (en) 2013-09-24 2019-03-21 Giner, Inc. System for gas treatment of a cell implant
CN113768881A (zh) 2013-10-08 2021-12-10 人工智能治疗公司 用于治疗淋巴管平滑肌瘤病的雷帕霉素
KR20160120739A (ko) 2014-02-11 2016-10-18 램 테라퓨틱스, 인코포레이티드 림프관평활근종증의 치료를 위한 라파마이신
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
RU2718583C2 (ru) 2014-04-04 2020-04-08 ЭйАй ТЕРАПЬЮТИКС, ИНК. Рапамицин-содержащая композиция, вводимая путем ингаляции для лечения возрастных заболеваний
WO2016057712A1 (en) 2014-10-07 2016-04-14 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
WO2016130645A1 (en) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US20190167649A1 (en) 2016-08-10 2019-06-06 The Board Of Regents Of The University Of Texas System Topical rapamycin therapy
US20190388210A1 (en) 2016-09-19 2019-12-26 Biotronik Ag Polymer-Free Drug Eluting Vascular Stents
BR112019009712A2 (pt) 2016-11-15 2019-08-13 Giner Life Sciences Inc dispositivo de difusão gasosa percutânea adequado para uso com um implante subcutâneo
JP7118061B2 (ja) 2016-12-22 2022-08-15 バイオトロニック アクチェンゲゼルシャフト 医療装置のための薬剤放出被膜およびその作製方法
CN110831656A (zh) 2017-05-04 2020-02-21 吉纳生命科学公司 稳健的可植入气体递送装置和方法、系统以及包括该装置的装置
UY37900A (es) 2017-09-26 2019-04-30 Novartis Ag Nuevos derivados de rapamicina
MX2021010058A (es) 2019-02-20 2021-11-12 Ai Therapeutics Inc Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US5364612A (en) * 1991-05-06 1994-11-15 Immunomedics, Inc. Detection of cardiovascular lesions
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
KR100284210B1 (ko) * 1992-04-28 2001-03-02 이건 이. 버그 과증식성 혈관 질환 치료용 배합 제제
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
JP3745772B2 (ja) * 1993-12-17 2006-02-15 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤として有用なラパマイシン誘導体
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6265427B1 (en) * 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
DK0833828T3 (da) * 1995-06-09 2003-03-17 Novartis Ag Rapamycinderivater
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds

Also Published As

Publication number Publication date
IL125812A (en) 2001-12-23
US20140187574A1 (en) 2014-07-03
EP0893996A1 (en) 1999-02-03
PT893996E (pt) 2002-12-31
WO1997035575A1 (en) 1997-10-02
HU226422B1 (en) 2008-12-29
US6384046B1 (en) 2002-05-07
JP2009102349A (ja) 2009-05-14
SK132798A3 (en) 1999-03-12
HK1018688A1 (en) 1999-12-30
US20120177690A1 (en) 2012-07-12
ZA972719B (en) 1998-09-28
EP2008657B1 (en) 2013-04-24
KR20050038656A (ko) 2005-04-27
CZ292483B6 (cs) 2003-09-17
ES2421455T3 (es) 2013-09-02
KR100836971B1 (ko) 2008-06-10
US20020127248A1 (en) 2002-09-12
SI2008657T1 (sl) 2013-07-31
RU2214247C2 (ru) 2003-10-20
PL187732B1 (pl) 2004-09-30
EP2008657A3 (en) 2009-02-04
AU716514B2 (en) 2000-02-24
CN1214631A (zh) 1999-04-21
NO984340D0 (no) 1998-09-18
US20100152105A1 (en) 2010-06-17
PL328659A1 (en) 1999-02-15
AU2291897A (en) 1997-10-17
ATE224194T1 (de) 2002-10-15
MY117798A (en) 2004-08-30
CA2247275A1 (en) 1997-10-02
CN1124135C (zh) 2003-10-15
EP0893996B1 (en) 2002-09-18
HUP0001267A3 (en) 2002-01-28
GB9606452D0 (en) 1996-06-05
BR9708358A (pt) 1999-08-03
KR20070083654A (ko) 2007-08-24
IL125812A0 (en) 1999-04-11
TR199801919T2 (xx) 1999-02-22
EP2008657A2 (en) 2008-12-31
DK0893996T3 (da) 2002-12-09
EP1149581A2 (en) 2001-10-31
JP5124431B2 (ja) 2013-01-23
ES2184078T3 (es) 2003-04-01
DE69715611D1 (de) 2002-10-24
EP1149581A3 (en) 2003-12-03
DE69715611T2 (de) 2003-05-22
HUP0001267A2 (hu) 2000-11-28
CY2404B1 (en) 2004-09-10
NO316667B1 (no) 2004-03-29
NO984340L (no) 1998-09-18
ID17195A (id) 1997-12-11
DK2008657T3 (da) 2013-07-22
JP2000507226A (ja) 2000-06-13
CA2247275C (en) 2011-10-11
CZ307098A3 (cs) 1999-01-13
PT2008657E (pt) 2013-07-12
NZ331463A (en) 2001-10-26

Similar Documents

Publication Publication Date Title
SK284343B6 (sk) Použitie 40-O-(2-hydroxy)etyl-rapamycínu
JP2009102349A6 (ja) 血管疾病および異種移植におけるラパマイシン誘導体の使用
JP4004070B2 (ja) １，３―プロパンジオール誘導体の新しい用途
KR100616020B1 (ko) 맥관장애및이종이식술에서의라파마이신유도체의용도

Legal Events

Date Code Title Description
MK4A Expiry of patent

Expiry date: 20170326